Glabinsk A R, Ransohoff R M
Department of Neurology. Medical University of Lodz, Poland.
Curr Opin Investig Drugs. 2001 Dec;2(12):1712-9.
Multiple sclerosis (MS) is the most common demyelinating disorder of the human central nervous system (CNS). The typical pathological hallmark of active MS is the presence of inflammatory foci disseminated in the CNS. It is believed that the composition of inflammatory infiltrates is determined in part by the spectrum of chemokines produced in a focus of inflammation. Numerous studies suggest chemokine involvement in MS pathogenesis. Interfering with chemokine-chemokine-receptor interactions may potentially lead to prevention and/or amelioration of CNS inflammatory processes. Initial studies to obtain 'proof-of-principle' used neutralizing antibodies in small animal models of MS. The subsequent generation of chemokine receptor inhibitors were modified chemokine peptides. At present, the development of small molecule antagonists to chemokine receptors is the dominant approach. Current evidence suggests that chemokines and their receptors are promising targets for effective treatment of MS and other CNS inflammatory and autoimmune diseases.
多发性硬化症（MS）是人类中枢神经系统（CNS）最常见的脱髓鞘疾病。活动性MS的典型病理标志是中枢神经系统中存在散在的炎症病灶。据信，炎症浸润的组成部分部分由炎症病灶中产生的趋化因子谱决定。大量研究表明趋化因子参与MS发病机制。干扰趋化因子-趋化因子-受体相互作用可能潜在地预防和/或改善中枢神经系统炎症过程。最初获得“原理证明”的研究在MS的小动物模型中使用了中和抗体。随后产生的趋化因子受体抑制剂是经过修饰的趋化因子肽。目前，开发针对趋化因子受体的小分子拮抗剂是主要方法。目前的证据表明，趋化因子及其受体是有效治疗MS和其他中枢神经系统炎症及自身免疫性疾病的有希望的靶点。
